Trial Profile
A phase I pharmacokinetic trial of novel liquid formulation of exendin 9-39
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2017
Price :
$35
*
At a glance
- Drugs Avexitide (Primary)
- Indications Hypoglycaemia
- Focus Pharmacokinetics
- 09 Nov 2017 Status changed from active, no longer recruiting to completed, according to an Eiger BioPharmaceuticals media release.
- 14 Aug 2017 According to an Eiger BioPharmaceuticals media release, status changed from recruiting to active, no longer recruiting.
- 14 Aug 2017 According to an Eiger BioPharmaceuticals media release, dosing in this trial has been completed.